Analyst Ratings For Adverum Biotechnologies (NASDAQ:ADVM)
Today, Piper Jaffray Companies initiated coverage on Adverum Biotechnologies (NASDAQ:ADVM) with a Buy with a price target of $12.00.
Some recent analyst ratings include
- 2/15/2018-Piper Jaffray Companies initiated coverage with a Buy rating.
- 12/19/2017-Chardan Capital Reiterated Rating of Hold.
- 10/12/2017-Raymond James Financial initiated coverage with a Outperform rating.
- 8/10/2016-Jefferies Group Reiterated Rating of Buy.
- 5/27/2016-Cowen initiated coverage with a Outperform rating.
Recent Insider Trading Activity For Adverum Biotechnologies (NASDAQ:ADVM)
Adverum Biotechnologies (NASDAQ:ADVM) has insider ownership of 7.80% and institutional ownership of 30.75%.
- On 6/8/2015 Mehdi Gasmi, VP, sold 500 with an average share price of $38.64 per share and the total transaction amounting to $19,320.00.
- On 6/8/2015 Paul Wachter, Director, sold 1,192 with an average share price of $38.64 per share and the total transaction amounting to $46,058.88.
- On 5/26/2015 Paul Wachter, Director, sold 1,192 with an average share price of $36.94 per share and the total transaction amounting to $44,032.48.
- On 5/22/2015 Steven Daniel Schwartz, Director, sold 16,875 with an average share price of $38.38 per share and the total transaction amounting to $647,662.50.
- On 5/13/2015 Linda Bain, CFO, sold 285 with an average share price of $34.94 per share and the total transaction amounting to $9,957.90.
- On 5/13/2015 Mark S Blumenkranz, Director, sold 715 with an average share price of $34.94 per share and the total transaction amounting to $24,982.10.
- On 5/8/2015 Steven Daniel Schwartz, Director, sold 17,250 with an average share price of $33.05 per share and the total transaction amounting to $570,112.50.
Recent Trading Activity for Adverum Biotechnologies (NASDAQ:ADVM)
Shares of Adverum Biotechnologies closed the previous trading session at 6.35 down -0.15 2.31% with 6.849999904632568 shares trading hands.